Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other financing activities (2016 - 2018)

Enanta Pharmaceuticals' Other financing activities history spans 7 years, with the latest figure at -$5.5 million for Q2 2018.

  • For Q2 2018, Other financing activities changed N/A year-over-year to -$5.5 million; the TTM value through Sep 2024 reached -$5.5 million, down 68.06%, while the annual FY2023 figure was $325000.0, N/A changed from the prior year.
  • Other financing activities reached -$5.5 million in Q2 2018 per ENTA's latest filing, down from $2.2 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $2.2 million in Q1 2018 to a low of -$5.5 million in Q2 2018.
  • Average Other financing activities over 5 years is -$222.22, with a median of -$2000.0 recorded in 2016.
  • Peak YoY movement for Other financing activities: crashed 160.0% in 2015, then surged 1767.65% in 2016.
  • A 5-year view of Other financing activities shows it stood at $1.9 million in 2014, then crashed by 100.16% to -$3000.0 in 2015, then soared by 33.33% to -$2000.0 in 2016, then tumbled by 12150.0% to -$245000.0 in 2017, then crashed by 2146.53% to -$5.5 million in 2018.
  • Per Business Quant, the three most recent readings for ENTA's Other financing activities are -$5.5 million (Q2 2018), $2.2 million (Q1 2018), and -$245000.0 (Q4 2017).